Aran Singanayagam 1, Nicholas Glanville 1, Jason L Girkin 2, Yee Man Ching 1, Andrea Marcellini 1, James D Porter
PMID: 29884817 PMCID: PMC5993715 DOI: 10.1038/s41467-018-04574-1
Abstract
Inhaled corticosteroids (ICS) have limited efficacy in reducing chronic obstructive pulmonary disease (COPD) exacerbations and increase pneumonia risk, through unknown mechanisms. Rhinoviruses precipitate most exacerbations and increase susceptibility to secondary bacterial infections. Here, we show that the ICS fluticasone propionate (FP) impairs innate and acquired antiviral immune responses leading to delayed virus clearance and previously unrecognised adverse effects of enhanced mucus, impaired antimicrobial peptide secretion and increased pulmonary bacterial load during virus-induced exacerbations. Exogenous interferon-β reverses these effects. FP suppression of interferon may occur through inhibition of TLR3- and RIG-I virus-sensing pathways. Mice deficient in the type I interferon-α/β receptor (IFNAR1−/−) have suppressed antimicrobial peptide and enhanced mucin responses to rhinovirus infection. This study identifies type I interferon as a central regulator of antibacterial immunity and mucus production. Suppression of interferon by ICS during virus-induced COPD exacerbations likely mediates pneumonia risk and raises suggestion that inhaled interferon-β therapy may protect.
Keywords: Adrenal Cortex Hormones / administration & dosage
Adrenal Cortex Hormones / immunology
Adrenal Cortex Hormones / pharmacology*
Animals
Bacterial Infections / microbiology
Bacterial Infections / prevention & control
Bacterial Load / drug effects*
Cell Line
Fluticasone / administration & dosage
Fluticasone / immunology
Fluticasone / pharmacology
Humans
Immunity, Innate / drug effects*
Lung / drug effects
Lung / microbiology
Lung / virology
Mice, Knockout
Mucus / drug effects*
Mucus / microbiology
Mucus / virology
Picornaviridae Infections / prevention & control
Picornaviridae Infections / virology
Pulmonary Disease, Chronic Obstructive / microbiology
Pulmonary Disease, Chronic Obstructive / prevention & control*
Pulmonary Disease, Chronic Obstructive / virology
Receptor, Interferon alpha-beta / genetics
Receptor, Interferon alpha-beta / metabolism
Rhinovirus / drug effects*
Rhinovirus / immunology
Rhinovirus / physiology
Source: https://pubmed.ncbi.nlm.nih.gov/33517482/
Archive: https://archive.is/8sMLe
